Suzuki Ryo, Kazumori Kiyoyasu, Usui Tatsuya, Shinohara Masahiko
Department of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, Tokyo, Japan.
Medical Science, Sumitomo Pharma Co., Ltd., Tokyo, Japan.
J Diabetes Investig. 2024 Aug;15(8):1057-1067. doi: 10.1111/jdi.14214. Epub 2024 Apr 18.
AIMS/INTRODUCTION: Despite the emergence of new drugs with novel mechanisms of action, treatment options for older people and those with chronic kidney disease are still limited.
Using a medical database compiled from Diagnostic Procedure Combination hospitals, we retrospectively analyzed treatment status, glycemic control and kidney function over 3 years after the first oral antidiabetic drugs in Japanese adults with type 2 diabetes who were aged ≥65 years.
Among 5,434 study participants, 3,246 (59.7%) were men, the median age was 72.0 years, the baseline median hemoglobin A1c was 7.1% and the baseline median estimated glomerular filtration rate was 66.6 mL/min/1.73 m. Treatment was intensified in 40.0% of people during the 3-year observation period, and the median time to the first treatment intensification was 198 days. Insulin was the most commonly used agent for treatment intensification (36.9%, 802/2,175). Hemoglobin A1c of <7.0% was achieved in 3,571 (65.7%) at 360 ± 90 days. Multivariable logistic regression analysis found that baseline age, hemoglobin A1c and estimated glomerular filtration rate were negatively associated with achieving hemoglobin A1c of <7.0% at 360 ± 90 days.
In older Japanese adults with type 2 diabetes, those with a lower estimated glomerular filtration rate were more likely to achieve hemoglobin A1c of <7.0%. To safely manage blood glucose levels in older adults with chronic kidney disease, physicians should remain vigilant about the risk of iatrogenic hypoglycemia.
目的/引言:尽管出现了具有新作用机制的新药,但老年人和慢性肾脏病患者的治疗选择仍然有限。
利用从诊断程序组合医院汇编的医学数据库,我们回顾性分析了年龄≥65岁的日本2型糖尿病成年患者首次口服抗糖尿病药物后3年的治疗状况、血糖控制和肾功能。
在5434名研究参与者中,3246名(59.7%)为男性,中位年龄为72.0岁,基线血红蛋白A1c中位数为7.1%,基线估计肾小球滤过率中位数为66.6 mL/min/1.73m²。在3年观察期内,40.0%的患者治疗得到强化,首次治疗强化的中位时间为198天。胰岛素是治疗强化最常用的药物(36.9%,802/2175)。在360±90天时,3571名(65.7%)患者的血红蛋白A1c<7.0%。多变量逻辑回归分析发现,基线年龄、血红蛋白A1c和估计肾小球滤过率与在360±90天时血红蛋白A1c<7.0%呈负相关。
在老年日本2型糖尿病患者中,估计肾小球滤过率较低的患者更有可能使血红蛋白A1c<7.0%。为安全管理慢性肾脏病老年患者的血糖水平,医生应警惕医源性低血糖风险。